Sean Eckley
Overview
Explore the profile of Sean Eckley including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
224
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vinayak S, Jumani R, Miller P, Hasan M, McLeod B, Tandel J, et al.
Sci Transl Med
. 2020 Oct;
12(563).
PMID: 32998973
is a protozoan parasite and a leading cause of diarrheal disease and mortality in young children. Currently, there are no fully effective treatments available to cure infection with this diarrheal...
2.
Puyang X, Furman C, Zheng G, Wu Z, Banka D, Aithal K, et al.
Cancer Discov
. 2018 Jul;
8(9):1176-1193.
PMID: 29991605
Mutations in estrogen receptor alpha (ERα) that confer resistance to existing classes of endocrine therapies are detected in up to 30% of patients who have relapsed during endocrine treatments. Because...
3.
Wozniak K, Vornov J, Wu Y, Liu Y, Carozzi V, Rodriguez-Menendez V, et al.
Cancer Res
. 2017 Dec;
78(3):817-829.
PMID: 29191802
Chemotherapy-induced peripheral neuropathy (CIPN) is a major cause of disability in cancer survivors. CIPN investigations in preclinical model systems have focused on either behaviors or acute changes in nerve conduction...
4.
Kato N, Comer E, Sakata-Kato T, Sharma A, Sharma M, Maetani M, et al.
Nature
. 2016 Sep;
538(7625):344-349.
PMID: 27602946
Antimalarial drugs have thus far been chiefly derived from two sources-natural products and synthetic drug-like compounds. Here we investigate whether antimalarial agents with novel mechanisms of action could be discovered...
5.
Narayan S, Carlson E, Cheng H, Condon K, Du H, Eckley S, et al.
Bioorg Med Chem Lett
. 2011 Feb;
21(6):1634-8.
PMID: 21324692
Eribulin mesylate is a newly approved treatment for locally advanced and metastatic breast cancer. We targeted oral bioavailability and efficacy against multidrug resistant (MDR) tumors for further work. The design,...
6.
Narayan S, Carlson E, Cheng H, Condon K, Du H, Eckley S, et al.
Bioorg Med Chem Lett
. 2011 Feb;
21(6):1639-43.
PMID: 21324687
Novel second generation analogs of eribulin mesylate, a tubulin agent recently approved for the treatment of breast cancer, are reported. Our recent efforts have focused on expanding the target indications...